Literature DB >> 21509674

Effect of Fufang Xueshuantong Capsule on a rat model of retinal vein occlusion.

Yuan-Zhi Yuan1, Fei Yuan, Qin-Yue Xu, Jia Yu, Lei Li, Ju-Li Zhang.   

Abstract

OBJECTIVE: To establish a retinal vein occlusion (RVO) animal model and observe the therapeutic effect of a Chinese herbal composition (Fufang Xueshuantong Capsule, , FXC)inischemicinischemic) in ischemic retinal disease.
METHODS: Fifteen adult male Sprague-Dawley rats underwent laser photothrombosis to induce RVO on their right eyes and were subsequently randomized to receive FXC (the intervention group, n=7) or placebo treatment (the control group, n=8). Fundus fluorescein angiography was performed after 2, 4 and 8 weeks of treatment. Real-time reverse transcription-PCR was used to quantify the mRNA expression of vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1 (SDF-1). The main outcomes were the mRNA copies of VEGF and SDF-1 and the counts of RVO signs.
RESULTS: Laser photothrombosis procedure induced typical lesions of RVO, including hemorrhage, leakage, retinal detachment, capillary non-perfusion, filling defect of retinal vessels, and lateral circulation/dilation of small vessels. The retinal lesions were associated with an increased expression of VEGF (P<0.05). No significant change of SDF-1 expression was noticed. Compared with the control group, the intervention group had numerically fewer RVO lesions at week 2 (1.71±0.76 vs. 3.50±1.51, t=-2.82, P<0.05). The benefit of intervention remained at weeks 4 and 8.
CONCLUSIONS: A rat model of laser photothrombosis-induced RVO was established and an increase in the VEGF expression was observed in the retinal lesion. The FXC had therapeutic benefit in improving retinal lesions in the rat model of RVO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21509674     DOI: 10.1007/s11655-011-0690-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  24 in total

1.  Angiogenesis and anti-angiogenesis activity of Chinese medicinal herbal extracts.

Authors:  Shanshan Wang; Zhengui Zheng; Yinqi Weng; Yijun Yu; Daifu Zhang; Weihu Fan; Ruihong Dai; Zhibi Hu
Journal:  Life Sci       Date:  2004-04-02       Impact factor: 5.037

Review 2.  Clinical practice. Retinal-vein occlusion.

Authors:  Tien Y Wong; Ingrid U Scott
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

3.  Prevalence and risk factors of retinal vein occlusion in an Asian population.

Authors:  L L Lim; N Cheung; J J Wang; F M A Islam; P Mitchell; S M Saw; T Aung; T Y Wong
Journal:  Br J Ophthalmol       Date:  2008-08-06       Impact factor: 4.638

4.  Experimental preretinal neovascularization by laser-induced venous thrombosis in rats.

Authors:  Y Saito; L Park; S A Skolik; D V Alfaro; N A Chaudhry; C J Barnstable; P E Liggett
Journal:  Curr Eye Res       Date:  1997-01       Impact factor: 2.424

Review 5.  Surgical treatment of central retinal vein occlusion.

Authors:  Nilufer Berker; Cosar Batman
Journal:  Acta Ophthalmol       Date:  2008-05       Impact factor: 3.761

6.  Stromal cell-derived factor 1alpha (SDF-1alpha) induces gene-expression of early growth response-1 (Egr-1) and VEGF in human arterial endothelial cells and enhances VEGF induced cell proliferation.

Authors:  Thomas Neuhaus; Sebastian Stier; Gudrun Totzke; Elisabeth Gruenewald; Stefan Fronhoffs; Agapios Sachinidis; Hans Vetter; Yon D Ko
Journal:  Cell Prolif       Date:  2003-04       Impact factor: 6.831

7.  SDF-1 is both necessary and sufficient to promote proliferative retinopathy.

Authors:  Jason M Butler; Steven M Guthrie; Mehmet Koc; Aqeela Afzal; Sergio Caballero; H Logan Brooks; Robert N Mames; Mark S Segal; Maria B Grant; Edward W Scott
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

8.  Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study.

Authors:  P Mitchell; W Smith; A Chang
Journal:  Arch Ophthalmol       Date:  1996-10

9.  In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus.

Authors:  William Chi Shing Cho; Kwok Nam Leung
Journal:  J Ethnopharmacol       Date:  2007-05-31       Impact factor: 4.360

10.  Natural history and histology in a rat model of laser-induced photothrombotic retinal vein occlusion.

Authors:  Yi Zhang; Brad Fortune; La-ongsri Atchaneeyasakul; Trevor McFarland; Kristen Mose; Patrick Wallace; Julianne Main; David Wilson; Binoy Appukuttan; J Timothy Stout
Journal:  Curr Eye Res       Date:  2008-04       Impact factor: 2.424

View more
  4 in total

1.  Effect of compatible herbs on the pharmacokinetics of effective components of Panax notoginseng in Fufang Xueshuantong Capsule.

Authors:  Huan-Huan Pang; Meng-Yi Li; Yuan Wang; Min-Ke Tang; Chang-Hua Ma; Jian-Mei Huang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Apr.       Impact factor: 3.066

Review 2.  Recent Update on the Role of Chinese Material Medica and Formulations in Diabetic Retinopathy.

Authors:  Sandeep Vasant More; In-Su Kim; Dong-Kug Choi
Journal:  Molecules       Date:  2017-01-04       Impact factor: 4.411

3.  Analysis of the Constituents in "Zhu She Yong Xue Shuan Tong" by Ultra High Performance Liquid Chromatography with Quadrupole Time-of-Flight Mass Spectrometry Combined with Preparative High Performance Liquid Chromatography.

Authors:  Lin-Lin Wang; Li-Feng Han; He-Shui Yu; Mang-Mang Sang; Er-Wei Liu; Yi Zhang; Shi-Ming Fang; Tao Wang; Xiu-Mei Gao
Journal:  Molecules       Date:  2015-11-18       Impact factor: 4.411

4.  Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration.

Authors:  Hai-Tao Pan; Jun-Jun Wang; Jun-Long Huang; Yuan-Lu Shuai; Jia Li; Zi-Zhong Hu; Yu-Zhi Ding; Qing-Huai Liu
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.